A Phase 3 interventional study of 0.5% standard bupivacaine only and 1.33% liposomal bupivacaine with 0.5% standard bupivacaine in Pain, Postoperative, Analgesic Effect and Total Knee Arthroplasty, sponsored by The University of Hong Kong. Recruiting at 1 site in Hong Kong. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-11-24.
Sponsored by The University of Hong Kong · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Pain, Postoperative by The University of Hong Kong — 3 open to participants now, 3 under way, 2 of them phase 3. Pain, Postoperative · The University of Hong Kong.
Among the 14 studies in Pain, Postoperative by The University of Hong Kong, this one is the 2nd largest by planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2025, is one of 4 in phase 3, and was the 13th registered.
5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.
Browse Pain, Postoperative studies →3 of the 14 studies in Pain, Postoperative by The University of Hong Kong are open now, in 1 country. Recruiting first, the newest first:
The University of Hong Kong · Sites in Hong Kong
Ages 18–90
The University of Hong Kong · Sites in Hong Kong
Ages 18–80
By country, each count listing its studies:
Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 177 is above the median of 75 across 4,859 interventional studies indexed under Pain, Postoperative.
Median enrollment 90 across the 11 interventional studies, 95 across the 3 observational. Of the 9 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
The University of Hong Kong is the lead sponsor of 1,295 studies on the registry; 351 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
1 of the studies in Pain, Postoperative by The University of Hong Kong that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06740214Phase 3The University of Hong KongAnalgesic Efficacy of Different Liposomal Bupivacaine Doses in the Adductor Canal Block for Total Knee Arthroplasty | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 14 studies in Pain, Postoperative by The University of Hong Kong, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Total knee arthroplasty is a commonly performed orthopaedic surgery for the treatment of end-stage osteoarthritis when conservative management becomes ineffective. TKA is associated with significant acute postoperative pain and many patients experience severe postoperative pain despite the use of multimodal analgesia. Poor acute postoperative pain control impacts rehabilitation, prolongs recovery and increases opioid consumption and chronic post-surgical pain.
Liposomal bupivacaine (Exparel, Pacira Pharmaceuticals Inc, Parsippany, New Jersey, USA) is a multivesicular formulation of bupivacaine that prolongs drug release and can extend the duration of analgesia. The adductor canal block (ACB) has been shown to reduce pain intensity and opioid consumption after total knee arthroplasty. The use of liposomal bupivacaine in the adductor canal block has recently been FDA-approved. However, the results of its efficacy from existing clinical trials have been mixed. In addition, the doses in the clinical trials have been different, and the optimal dose for perineural application of liposomal bupivacaine is unclear, including for the adductor canal block.
In this project, the investigators propose to conduct a randomized controlled trial to investigate the effect of different doses of liposomal bupivacaine in the adductor canal block on acute postoperative pain intensity and opioid consumption after robotic assisted total knee arthroplasty. The investigators will also assess secondary outcomes including knee functional scores, chronic pain and quality of recovery.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
adductor canal block with 20ml 0.5% standard bupivacaine only
Drug: 0.5% standard bupivacaine only
adductor canal block with 10ml 1.33% liposomal bupivacaine (133mg) plus 10ml 0.5% standard bupivacaine
Drug: 1.33% liposomal bupivacaine with 0.5% standard bupivacaine
adductor canal block with 20ml 1.33% liposomal bupivacaine (266mg)
Drug: 1.33% liposomal bupivacaine only
20ml 0.5% standard bupivacaine only
10ml 1.33% liposomal bupivacaine (133mg) plus 10ml 0.5% standard bupivacaine
20ml 1.33% liposomal bupivacaine (266mg)
Weighted area under curve (AUC) pain score
Pain severity would be rated at rest after surgery using numerical rating scale (NRS) with 0 to 10 where 0=no pain and 10=the worst possible pain
Time frame: The first 48 hours after surgery when the patient is at rest
NRS pain scores
NRS pain scores at rest and with movement (active knee flexion) from after surgery to postoperative day (POD) 7, ranging 0-10, with higher scores indicating more severe pain.
Time frame: from after surgery to postoperative day 7
Oxynorm consumption
Oxynorm consumption from postoperative day (POD) 1-7
Time frame: Postoperative day 1-7
Overall Benefit of Analgesic Score (OBAS)
Overall Benefit of Analgesic Score (OBAS) from postoperative day (POD) 1-7 (range, 0 \[best\] to 28 \[worst\])
Time frame: Postoperative day (POD) 1-7
Plasma level of bupivacaine and ropivacaine
Plasma level of bupivacaine and ropivacaine before and after surgery
Time frame: Blood will be collected during induction, at 12 hours, 24 hours, 48 hours, and 72 hours after ACB.
Quality of Recovery Questionnaire (QoR-9)
Quality of Recovery Questionnaire (QoR-9) on postoperative day 1, ranging from 0 to 18, with higher scores indicating good recovery after anaesthesia.
Time frame: Postoperative day 1
Rehabilitation parameters (range of maximal active knee flexion)
Range of maximal active knee flexion will be assessed by the physiotherapists while the patient is in hospital.
Time frame: While the patient is in hospital from postoperative day 0, day 1, and day 2.
Rehabilitation parameters (quadricep power)
Quadricep power will be assessed by the physiotherapists while the patient is in hospital. Ratings: 0 - no muscle contraction 1. \- Move w/o gravity 2. \- Raise then drop down immediately 3. \- Raise against gravity w/o resistance 4. \- Raise against gravity w/some resistance 5. \- Raise against gravity w/ full resistance
Time frame: While the patient is in hospital from postoperative day 0, day 1, and day 2.
Rehabilitation parameters (ability to perform straight leg raising)
Ability to perform straight leg raising will be assessed by the physiotherapists while the patient is in hospital. Ratings (Yes/ No).
Time frame: While the patient is in hospital from postoperative day 0, day 1, and day 2.
Rehabilitation parameters (walking distance)
Walking distance (in metres) will be assessed by the physiotherapists while the patient is in hospital.
Time frame: While the patient is in hospital from postoperative day 0, day 1, and day 2.
Rehabilitation parameters (Duration of hospital stay)
No. of hospitalization days from admission to discharge
Time frame: estimated on average of postoperative day 7 at the date of discharge from hospital
Rehabilitation parameters (discharge location)
Home or rehabilitation center
Time frame: estimated on average of postoperative day 7 at the date of discharge from hospital
Opioid-related side effects
Presence or absence of pruritus, dizziness, nausea, and vomiting will be recorded.
Time frame: While the patient is in hospital from postoperative day 0, 1, and 2.
Potential side effects related to adductor canal block (ACB)
Presence or absence of local anaesthetic toxicity, neurological injury, and intravascular injection will be recorded.
Time frame: While the patient is in hospital from postoperative day 0, 1, and 2.
Analgesic block duration
Measured in time to return of pain (When did your pain relief from the block completely wear off?), time to sensory resolution (When did your numbness completely resolve and return to normal?), and time to motor resolution (When did your arm or hand weakness resolve and return to normal?)
Time frame: While the patient is in hospital at postoperative day 1
Sensory and motor assessment
The affected lower limb will be measured. Sensory assessment (Sensation to pin prick), rating from 0 (no sensation) to 10 (normal sensation) Motor assessment * Straight leg raising achieved Ratings (Yes/ No) * Quadriceps power Ratings: 0 - no muscle contraction 1. \- Move w/o gravity 2. \- Raise then drop down immediately 3. \- Raise against gravity w/o resistance 4. \- Raise against gravity w/some resistance 5. \- Raise against gravity w/ full resistance
Time frame: While the patient is in hospital from post-block 2 hours, 6 hours, 12 hours, and 24 hours.
quality of life (SF12v2)
Eight domains of SF-12v2 (HK) are measured on a scale ranging from 0 to 100. A higher domain score indicates a better HRQoL.
Time frame: at 6 weeks and at 3 and 6 months after surgery
Identification Pain Questionnaire for Neuropathic Pain (ID-NeP)
Neuropathic pain will be assessed using Identification Pain Questionnaire for Neuropathic Pain (ID-NeP), consisting of six items: "Yes" answers to questions 1-5 were given a score of 1, while "yes" answer to question 6 scored -1. "No" answers to questions 1-5 were given a score of 0, while "yes" answer to question 6 scored 0.
Time frame: at 6 weeks, 3 months and 6 months postoperatively
Knee Society Knee Function Score
Knee Society Knee Function Score at 6 weeks, 3 months and 6 months postoperatively, from 0 to 100 with lower scores being indicative of worse knee conditions and higher scores being indicative of better knee conditions.
Time frame: at 6 weeks, 3 months and 6 months postoperatively
Chronic post-surgical pain
The presence or absence of chronic post-surgical pain, pain scores if present.
Time frame: at 6 weeks, 3 months and 6 months postoperatively
Started Sep 2025 (actual). Primary completion is estimated for Jun 2027, 21 months after the start.
Of 124 non-industry phase 3 interventional studies under Pain, Postoperative, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 21 months is close to that.
Counting every sponsor, half of 167 studies reached it within 17 months; a quarter within 8 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.